Ironwood Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Ironwood Pharmaceuticals
IRWD Stock  USD 4.54  0.10  2.16%   
Ironwood Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Ironwood Pharmaceuticals' valuation are provided below:
Gross Profit
344.2 M
Profit Margin
0.0842
Market Capitalization
754.8 M
Enterprise Value Revenue
3.5773
Revenue
339 M
There are over one hundred nineteen available fundamental trends for Ironwood Pharmaceuticals, which can be analyzed over time and compared to other ratios. Investors should ensure to confirm all of Ironwood Pharmaceuticals' regular performance against the performance from 2010 to 2026 to make sure the company is sustainable down the road. The current year's Market Cap is expected to grow to about 2.1 B. The current year's Enterprise Value is expected to grow to about 2.4 B

Ironwood Pharmaceuticals Total Revenue

227.88 Million

Check Ironwood Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Ironwood Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.7 M, Interest Expense of 20.1 M or Total Revenue of 227.9 M, as well as many indicators such as Price To Sales Ratio of 2.19, Dividend Yield of 0.0 or Days Sales Outstanding of 139. Ironwood financial statements analysis is a perfect complement when working with Ironwood Pharmaceuticals Valuation or Volatility modules.
  
Build AI portfolio with Ironwood Stock
Check out the analysis of Ironwood Pharmaceuticals Correlation against competitors.
For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.

Ironwood Pharmaceuticals Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Common Stock Shares Outstanding140.8 M184.1 M144.2 M
Slightly volatile
Total Assets493.2 M403.5 M491.9 M
Slightly volatile
Short and Long Term Debt Total723.9 M689.4 M378.5 M
Slightly volatile
Other Current Liabilities35.9 M35.6 M34.8 M
Slightly volatile
Total Current Liabilities81.9 M44.7 M76.9 M
Pretty Stable
Other Liabilities8.3 M8.8 M41.6 M
Slightly volatile
Property Plant And Equipment Net19.2 M14 M22.6 M
Slightly volatile
Current Deferred Revenue1.7 M1.8 M9.6 M
Pretty Stable
Accounts Payable1.8 M1.9 M7.8 M
Slightly volatile
Cash200.7 M101.8 M197.1 M
Slightly volatile
Non Current Assets Total145.4 M193.8 M153.6 M
Slightly volatile
Non Currrent Assets Other6.5 M6.8 M47.7 M
Very volatile
Other Assets1.091.1573.3 M
Pretty Stable
Long Term Debt705.2 M671.6 M344.3 M
Slightly volatile
Cash And Short Term Investments96.8 M101.8 M247.4 M
Very volatile
Net Receivables63.2 M94.2 M69.2 M
Slightly volatile
Common Stock Total Equity125.3 K177.1 K136.4 K
Slightly volatile
Liabilities And Stockholders Equity493.2 M403.5 M491.9 M
Slightly volatile
Non Current Liabilities Total387.5 M705.4 M389.4 M
Slightly volatile
Other Current Assets9.4 M13.7 M8.9 M
Slightly volatile
Other Stockholder Equity1.1 B1.6 B1.2 B
Slightly volatile
Total Liabilities469.4 M750.1 M466.3 M
Slightly volatile
Property Plant And Equipment Gross20 M21.5 M24.1 M
Pretty Stable
Total Current Assets347.8 M209.7 M338.2 M
Slightly volatile
Short Term Debt3.5 M3.7 M26.9 M
Slightly volatile
Common Stock130.7 K184 K137.6 K
Slightly volatile
Property Plant Equipment5.4 M5.7 M17.2 M
Slightly volatile
Long Term Debt Total311.5 M455.7 M291.7 M
Slightly volatile
Capital Surpluse1.3 B1.6 B1.2 B
Slightly volatile
Capital Lease Obligations10.4 M17.8 M9.5 M
Slightly volatile
Deferred Long Term Liabilities13.2 M13.9 M34.3 M
Slightly volatile
Non Current Liabilities Other12.3 M15.4 M13.2 M
Pretty Stable
Short and Long Term Debt184.4 M229.5 M133.2 M
Slightly volatile
Long Term Investments12.5 M13.1 M58.5 M
Slightly volatile
Net Invested Capital400.9 M325.1 M381.4 M
Slightly volatile
Capital Stock173.6 K184 K158.5 K
Slightly volatile

Ironwood Pharmaceuticals Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization1.7 M1.8 M6.8 M
Slightly volatile
Interest Expense20.1 M38 M23.8 M
Slightly volatile
Total Revenue227.9 M404.1 M262.1 M
Slightly volatile
Other Operating Expenses302.6 M297 M321.6 M
Slightly volatile
Research Development106.2 M128.1 M105.2 M
Pretty Stable
Cost Of Revenue6.5 M6.8 M26.5 M
Pretty Stable
Total Operating Expenses284.5 M288.3 M301.6 M
Slightly volatile
Gross Profit221.3 M395.4 M243.3 M
Slightly volatile
Selling General Administrative140 M165.9 M136.2 M
Slightly volatile
Non Recurring16.8 M17.7 M23.7 M
Very volatile
Interest Income7.1 M4 M17.8 M
Slightly volatile
Reconciled Depreciation1.7 M1.8 M8.8 M
Slightly volatile

Ironwood Pharmaceuticals Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation1.7 M1.8 M6.9 M
Slightly volatile
Capital Expenditures121.4 K127.8 K10 M
Pretty Stable
End Period Cash Flow193.6 M101.8 M196.6 M
Slightly volatile
Stock Based Compensation24.3 M34.3 M26 M
Slightly volatile
Begin Period Cash Flow199.3 M106 M195 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio2.192.3111.7055
Slightly volatile
Days Sales Outstanding13997.81137
Slightly volatile
Stock Based Compensation To Revenue0.190.09770.1676
Slightly volatile
Capex To Depreciation0.07710.08121.0897
Slightly volatile
EV To Sales3.783.9811.0629
Slightly volatile
Inventory Turnover0.971.0227.1359
Very volatile
Days Of Inventory On Hand672370699
Slightly volatile
Payables Turnover3.043.27.3655
Pretty Stable
Sales General And Administrative To Revenue1.380.81.0715
Pretty Stable
Research And Ddevelopement To Revenue0.350.361.3813
Slightly volatile
Capex To Revenue4.0E-45.0E-40.1221
Slightly volatile
Cash Per Share0.610.642.434
Slightly volatile
Days Payables Outstanding11211817.1 K
Pretty Stable
Intangibles To Total Assets0.00890.00940.1161
Slightly volatile
Current Ratio4.924.236.5136
Pretty Stable
Receivables Turnover4.694.9415.2241
Slightly volatile
Capex Per Share0.0010.0010.0959
Slightly volatile
Revenue Per Share1.531.991.7334
Slightly volatile
Interest Debt Per Share3.763.582.5438
Slightly volatile
Debt To Assets1.611.540.7829
Slightly volatile
Graham Number7.829.355.3858
Slightly volatile
Operating Cycle92.9297.81385
Slightly volatile
Days Of Payables Outstanding11211817.1 K
Pretty Stable
Ebt Per Ebit1.130.811.0327
Slightly volatile
Quick Ratio5.054.236.4724
Pretty Stable
Net Income Per E B T0.01470.01550.607
Very volatile
Cash Ratio3.062.054.074
Pretty Stable
Days Of Inventory Outstanding672370699
Slightly volatile
Days Of Sales Outstanding13997.81137
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.491.151.2779
Very volatile
Fixed Asset Turnover21.3920.3713.2912
Slightly volatile
Debt Ratio1.611.540.7829
Slightly volatile
Price Sales Ratio2.192.3111.7055
Slightly volatile
Asset Turnover0.950.90.5772
Slightly volatile
Gross Profit Margin0.720.880.896
Very volatile

Ironwood Pharmaceuticals Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap2.1 B2 B1.9 B
Slightly volatile
Enterprise Value2.4 B2.2 B2.1 B
Slightly volatile

Ironwood Fundamental Market Drivers

Forward Price Earnings12.3305
Cash And Short Term Investments88.6 M

Ironwood Upcoming Events

15th of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
15th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Ironwood Pharmaceuticals Financial Statements

Ironwood Pharmaceuticals stakeholders use historical fundamental indicators, such as Ironwood Pharmaceuticals' revenue or net income, to determine how well the company is positioned to perform in the future. Although Ironwood Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. For example, changes in Ironwood Pharmaceuticals' assets and liabilities are reflected in the revenues and expenses on Ironwood Pharmaceuticals' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Ironwood Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Current Deferred Revenue1.8 M1.7 M
Total Revenue404.1 M227.9 M
Cost Of Revenue6.8 M6.5 M
Stock Based Compensation To Revenue 0.10  0.19 
Sales General And Administrative To Revenue 0.80  1.38 
Research And Ddevelopement To Revenue 0.36  0.35 
Revenue Per Share 1.99  1.53 
Ebit Per Revenue 0.24  0.25 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
GOOGAlphabet Inc Class C
VVisa Class A
MSFTMicrosoft
When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:
How To Invest In Ironwood
Details
Is Ironwood Stock a good investment?
Details
What is Ironwood Pharmaceuticals' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Ironwood Pharmaceuticals Correlation against competitors.
For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.
You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
10.468
Earnings Share
0.18
Revenue Per Share
2.103
Quarterly Revenue Growth
0.333
Return On Assets
0.2288
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY